EMVision, an Australian medical device company focused on developing innovative portable brain imaging technology, has announced a US$10 million (~A$15.28m) strategic investment from Keysight Technologies, a global leader in test and measurement technology.

专注于开发创新便携式脑成像技术的澳大利亚医疗器械公司EMVision宣布，全球测试和测量技术领导者Keysight Technologies将对其进行1000万美元（约1528万澳元）的战略投资。

The investment provides EMVision with a fully funded commercial runway for its emu™ device. It accelerates clinical trials, generating essential data supporting the upcoming regulatory approval pathway and adoption in the world’s largest healthcare market. The new capital will also increase the company's production capacity for additional emu™ devices to be used in expanded clinical trials, including leading stroke centres in the United States..

这项投资为EMVision的emu™设备提供了一条资金充足的商业跑道。它加速了临床试验，产生了支持即将到来的监管批准途径的基本数据，并在世界最大的医疗保健市场中得到采用。新资本还将增加公司额外emu™设备的生产能力，用于扩大临床试验，包括美国领先的中风中心。

With a market capitalisation of approximately US$26 billion, the deal marks Keysight’s first investment globally in enabling innovation in point-of-care medical imaging, demonstrating its strong support for the clinical and commercial value of EMVision's innovative neuroimaging technology.

该交易的市值约为260亿美元，标志着Keysight首次在全球范围内进行投资，以实现即时医疗成像的创新，表明其对EMVision创新神经成像技术的临床和商业价值的有力支持。

EMVision's emu™ brain scanner is a pioneering advancement in stroke care, intended to provide rapid diagnostic imaging to accelerate the delivery of urgent, life-saving care, particularly in settings where traditional imaging modalities such as CT and MRI are not readily available.

EMVision的emu™脑部扫描仪是中风护理领域的一项开创性进展，旨在提供快速诊断成像，以加速紧急救生护理的提供，特别是在传统成像方式（如CT和MRI）不易获得的环境中。

The device is operated at the point of care, with a simple cap placed on the patient's head for quick scans and image generation. It couples safe, ultra-high frequency radio signals with powerful Artificial Intelligence to produce rapid insights directly at the patient’s bedside.

该设备在护理点操作，在患者头部放置一个简单的盖子，用于快速扫描和图像生成。它将安全的超高频无线电信号与强大的人工智能相结合，直接在患者床边产生快速的洞察力。

emu™ can be operated by any healthcare professional with minimal training. Targeted for use in intensive care units, stroke and neurology wards, and rural emergency departments, emu™ has the potential to improve survival rates and quality of life after stroke and other neurological events requiring urgent intervention..

emu™可以由任何医疗保健专业人员进行操作，只需很少的培训。emu™适用于重症监护病房、中风和神经科病房以及农村急诊科，有可能提高中风和其他需要紧急干预的神经系统事件后的生存率和生活质量。

The investment follows an original equipment manufacturer (OEM) supply partnership entered into by both companies in 2022, whereby EMVision secured exclusivity in the neuroimaging field for the VNA “fast sweep” feature. This component acts as the ‘brain’ of all EMVision devices, giving the company a substantial competitive advantage..

这项投资是在两家公司于2022年签订原始设备制造商（OEM）供应合作关系之后进行的，根据该合作关系，EMVision在神经影像领域为VNA“快速扫描”功能获得了独家经营权。该组件充当所有EMVision设备的“大脑”，为公司提供了巨大的竞争优势。

Scott Kirkland, Founder and CEO at EMVision, said, “Keysight's investment is an endorsement of our mission to improve global stroke outcomes and we're thrilled to embark on this next phase of growth together. Their commitment to being at the frontline of innovation aligns perfectly with EMVision's progress towards making ubiquitous portable brain imaging a reality.”.

EMVision创始人兼首席执行官斯科特·柯克兰德（ScottKirkland）表示：“Keysight的投资是对我们改善全球卒中结局使命的认可，我们很高兴能够共同开始下一阶段的发展。他们致力于创新的前沿，这与EMVision在实现无处不在的便携式脑成像方面取得的进展完全吻合。”

Huei Sin, Keysight Technologies President, Electronic Industrial Solutions Group, said, “We are delighted to strengthen our relationship with EMVision as we forge ahead in pioneering ground-breaking advancements in medical imaging technology. Keysight's technology leadership, particularly our industry-leading data acquisition speeds, alongside EMVision's brain scanning innovation, strategically positions our companies to spearhead significant developments in cutting-edge imaging solutions.”.

电子工业解决方案集团Keysight Technologies总裁Huei Sin表示，（笑声）“我们很高兴加强与EMVision的关系，在医学成像技术的开创性进步中不断前进。Keysight的技术领先地位，特别是我们业界领先的数据采集速度，以及EMVision的大脑扫描创新，在战略上使我们的公司能够引领尖端成像技术的重大发展解决方案。”

EMVision is also developing a first responder device. The backpack-sized scanners will weigh less than 10 kilograms and are intended for deployment via road and air ambulances. It would allow paramedics to scan and send images to specialists from the site of a suspected stroke, meaning patients could be diagnosed and treated more quickly than has previously been possible.

EMVision还正在开发一种急救设备。背包大小的扫描仪重量不到10公斤，计划通过公路和空中救护车部署。它将允许医护人员从疑似中风的部位扫描并向专家发送图像，这意味着患者可以比以前更快地得到诊断和治疗。

Market entry for the emu™ device is planned for next year, with the first responder device to follow..

emu™设备计划于明年进入市场，随后将推出首个响应设备。

Under the agreement, Keysight will be issued 7,454,231 new ordinary shares in EMVision at A$2.05 per share to acquire an 8.73% shareholding in EMVision. The agreement and issue of shares to Keysight, which will occur with EMVision's existing Listing Rule 7.1 headroom without the need for shareholder approval, is expected to be completed in the next two days..

根据协议，Keysight将以每股2.05澳元的价格在EMVision发行7454231股新普通股，以收购EMVision 8.73%的股权。预计将在未来两天内完成与Keysight的协议和股份发行，该协议将根据EMVision现有的上市规则7.1净空进行，无需股东批准。

The emu™️ and the first responder device are neither available for sale nor evaluated by the FDA or other global regulators. The devices may only be used by authorized sites in controlled clinical investigations.

emu™️ 第一反应器设备既不可销售，也未经FDA或其他全球监管机构评估。这些设备只能由授权地点在受控临床研究中使用。

About EMVision

关于EMVision

EMVision Medical Devices Limited (ASX:EMV) is an innovative Australian medical device company developing a novel approach to looking inside the human body. Our product pipeline includes portable, non-invasive, affordable and safe neuroimaging devices. Our vision is to help transform and improve the timely diagnosis and treatment of stroke and other time-sensitive medical emergencies at the point of care.

EMVision Medical Devices Limited（ASX:EMV）是一家创新的澳大利亚医疗器械公司，开发了一种新颖的人体内部观察方法。我们的产品线包括便携式、非侵入性、价格合理且安全的神经成像设备。我们的愿景是帮助改变和改善中风和其他对时间敏感的医疗紧急情况在护理点的及时诊断和治疗。

EMVision has offices in Sydney and Brisbane www.emvisionmedical.com.

EMVision在悉尼和布里斯班设有办事处www.emvisionmedical.com。

About Keysight Technologies

关于Keysight Technologies

At Keysight (NYSE: KEYS), we inspire and empower innovators to bring world-changing technologies to life. As an S&P 500 company, we're delivering market-leading design, emulation, and test solutions to help engineers develop and deploy faster, with less risk, throughout the entire product lifecycle.

在Keysight（纽约证券交易所代码：KEYS），我们激励和授权创新者将改变世界的技术带入生活。作为一家标准普尔500指数公司，我们正在提供市场领先的设计、仿真和测试解决方案，以帮助工程师在整个产品生命周期中以更低的风险更快地开发和部署。

We're a global innovation leader enabling customers in communications, industrial automation, aerospace and defence, automotive, semiconductor, and general electronics markets to accelerate innovation to connect and secure the world. Learn more at Keysight Newsroom and www.keysight.com..

我们是全球创新领导者，能够帮助通信、工业自动化、航空航天和国防、汽车、半导体和通用电子市场的客户加速创新，以连接和保护世界。更多信息，请访问Keysight新闻编辑室和www.Keysight.com。